blue strip-01.jpg

Our News & Views


Read our monthly Blog, Case Studies and White Papers to learn more about how we optimize market access for Channel/Trade, Payer and Patient Services



Image 2 Reimbursement.jpeg

Faith Dobson, Senior Consultant

blue feather-01.png

Understanding Your Reimbursement Landscape

When working with commercial teams for buy-and-bill specialty products, I often hear one of the goals is to build an effective reimbursement strategy. As commercial teams work to...(read more)

Image 3 for Channel Strategy (002).jpeg

Paul Callahan, Principal and Joe Cappello, Senior Consultant

blue feather-01.png

Competitive Benchmarking In Trade –

Answering The Who, What, Why and When

Last month our colleague Derek Cothran addressed the importance of using secondary research to benchmark your Patient Support Program (PSP) against obvious and not-so-obvious competitors....(read more)


Derek Cothran, Principal

blue feather-01.png

Are You Benchmarking Your PSP Against Others? If So, Who and What Are You Comparing It Against?

Many of our clients are looking for ways to ensure their Patient Support Program (PSP) is not only serving their patient and provider populations well but that it is doing so in a fiscally...(read more)

Collaboration 2.jpeg

David Robinson, Partner and Bryan Tyo, Senior Consultant

blue feather-01.png

Collaboration – A Key Component to the Long-term Success of Your Buy & Bill Launch Strategy

It has long been our observation that when clients are developing their launch services strategies for buy-and-bill (B&B) products, it is not typical for them to include their commercial sales...(read more)

patient-satisfaction 3.png

By Lee Ann Steadman, Partner 

blue feather-01.png

Are You Tracking the Performance and Satisfaction Ratings of Your Patient Services?

The types of services patients need for support change and fluctuate over time, particularly as a product moves through its lifecycle. The patient services necessary to drive access...(read more)


By Mike Scott, Partner and Paul Callahan, Principal

blue feather-01.png

How Specialty Pharmacies Can Elevate Your Channel and Distribution Strategy for HCP-administered Buy & Bill Products

A successful channel and distribution strategy for Buy & Bill (B&B) products should be centered around the partners you sell to and through. That means considering any third-party...(read more)


By Derek Cothran, Principal and Paul Maurer, Senior Consultant

blue feather-01.png

Making Sense of the CMS Final Rule: Value-Based Purchasing, Copay Accumulators and Best Price

On the last day of 2020, the CMS final rule was published in the Federal Register. The draft rule, published in June 2020, received tens of thousands of comments throughout the public...(read more)

image for mike psp blog.jpg

By Mike Scott, Partner 

blue feather-01.png

Five Things You Should Do to Ensure Your PSP Is Ready for Launch Before Your Brand Is

Your brand is preparing for launch, and it's time to develop a strategy for your Patient Support Program (PSP). Even if you already have one or more PSPs in place for your company's...(read more)


By Reid Saleeby, Partner

blue feather-01.png

Benchmarking Your Specialty Brand's Rx Pull-through Against Competitors In and Out of Your Network

As an executive at a specialty drug manufacturer, you know having access to your brand's pull-through key performance indicators (KPIs) inside your network is only a very...(read more)

copay image for blog.jpg

By David Robinson, Partner & Derek Cothran, Senior Consultant

blue feather-01.png

Copay Accumulator & Maximizer Programs are Changing - Is Your Strategy?

Copay assistance programs are a known tactic deployed by drug manufacturers to help facilitate access to often expensive speciality medications.  These financial assistance programs...(read more)


Case Studies


By Mike Scott, Partner & Paul Callahan, Principal

blue feather-01.png

Developing a Channel Strategy Through Benchmarking For a First-in-Class Product Portfolio

First-in-class products are designated as such because they have a differentiated Mechanism of Action (MOA) than those currently on the market. Innovative and developed to provide...(read more)

Expsoure Modeling.png

By John Chatas, Senior Consultant

blue feather-01.png

How Pre-Launch Financial Exposure Modeling and Planning Can Help a Biopharmaceutical Reach More Patients

It is anticipated that within the next 8 years up to 50% of all drugs in development will be biopharmaceuticals. As the development and subsequent use of biopharmaceuticals rise, so does...(read more)


By Reid Saleeby, Partner & Paul Maurer, Senior Consultant

blue feather-01.png

Using Survey Research to Develop Payer Strategies for an Existing Biologic’s Unique Indication in a Highly Competitive Market

Profitably managing a product through its lifecycle in highly competitive therapeutic markets presents an abundance of challenges. Pharmaceutical executives must...(read more)


By Reid Saleeby, Partner & David Frey, Principal

blue feather-01.png

Helping a Client with an Injectable Brand Gain Critical Site of Care Data and Insights with Rx Benchmarks


Biopharmaceutical managers like yourself often struggle with knowing exactly how their specialty brand is being prescribed and administered compared to competitors...(read more)


By Mike Scott, Partner & David Frey, Senior Consultant

blue feather-01.png

Developing a PSP Strategy that Identifies and Addresses Unique Therapeutic Challenges

When healthcare providers are faced with the need to initiate or switch therapy for patients with chronic medical conditions, a key goal is to optimize clinical response and tolerability...(read more)

headset case study pic.jpg

By Lee Ann Steadman, Partner & John Chatas, Senior Consultant

blue feather-01.png

How Protean Helped a Pharmaceutical Manufacturer Monitor the Quality of Their Patient Support Programs

Many pharmaceutical manufacturers have lacked the ability to monitor, track and report on the performance of their Patient Support Programs (PSP) offerings. More specifically,...(read more)


White Papers

Screen Shot 2021-08-12 at 1.05.06 PM.png

By Lee Ann Steadman, Partner & Mike Scott, Partner

blue feather-01.png

How Manufacturers Can Optimize and Organize Support Services for Specialty Drugs Through a Patient Touchpoint Analysis

Currently representing almost half of the overall pharmacy benefit spend, specialty drugs are classified as being high-complexity, high-touch and high-cost medications.As healthcare providers (HCPs) and patients turn to these more expensive products to treat rare, complex and/or chronic medical conditions, the need for...(read more)

Image for PSP whitepaper teaser.jpg

By Lee Ann Steadman, Partner & John Chatas, Senior Consultant

blue feather-01.png

Optimizing the Performance of a PSP and Improving Outcomes For All Stakeholders

Patient Support Programs (PSP) have been proven to improve clinical and patient outcomes and help manage patient out-of-pocket cost and prescribed use. The challenge has been with ensuring a PSP is evolving and maturing in a way that aligns with patient and stakeholder needs as well as the product's life cycle...(read more)